TriSalus Life Sciences, Inc. (TLSI) – What Are Analysts Saying About This Stock?

Posted by Francis Steltz on Nov 5th, 2026

TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Get Free Report) has been given a consensus rating of “Hold” by the five research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $10.20.

TLSI has been the subject of a number of research reports. Stifel Nicolaus set a $12.00 price target on shares of TriSalus Life Sciences in a report on Wednesday, September 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. HC Wainwright boosted their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, September 23rd. Guggenheim set a $12.00 price objective on shares of TriSalus Life Sciences in a research report on Wednesday, September 23rd. Finally, Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd.

View Our Latest Stock Report on TriSalus Life Sciences

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in TLSI. Cura Wealth Advisors LLC acquired a new stake in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $36,000. Provenance Wealth Advisors LLC acquired a new position in shares of TriSalus Life Sciences in the third quarter valued at $94,000. Renaissance Technologies LLC acquired a new position in shares of TriSalus Life Sciences in the first quarter valued at $124,000. Deutsche Bank AG bought a new position in TriSalus Life Sciences in the second quarter worth $221,000. Finally, Sei Investments Co. bought a new position in TriSalus Life Sciences in the first quarter worth $275,000. 2.58% of the stock is currently owned by institutional investors.

TriSalus Life Sciences Price Performance

TLSI opened at $3.89 on Thursday. The business has a 50 day moving average of $4.34 and a 200-day moving average of $4.38. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97. TriSalus Life Sciences has a 1-year low of $2.20 and a 1-year high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). The company had revenue of $11.41 million for the quarter, compared to the consensus estimate of $10.27 million. On average, equities analysts expect that TriSalus Life Sciences will post -0.53 EPS for the current fiscal year.

TriSalus Life Sciences Company Profile

(Get Free Report)

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.